Donanemab

Introduction Overview

Generic Name

donanemab

Brand Name

Kisunla

Dosage Form

injection for intravenous use (350 mg/20 mL)

Drug Class

Miscellaneous central nervous system agents

Pharmacokinetics

Absorption:
Donanemab (Kisunla) is administered intravenously, resulting in 100% bioavailability as it bypasses gastrointestinal absorption. Following IV infusion over approximately 30 minutes, donanemab rapidly enters systemic circulation, allowing predictable plasma concentrations to be achieved without first-pass metabolism. Absorption variability is minimal due to the controlled infusion process.

Distribution:
Donanemab, a monoclonal antibody, primarily distributes within the vascular and interstitial spaces. Given its large molecular weight (~150 kDa), tissue penetration is limited, with blood-brain barrier (BBB) penetration occurring through receptor-mediated or paracellular transport at low levels. The drug selectively targets amyloid beta plaques in the brain. Volume of distribution approximates plasma and extracellular fluid volumes. The distribution is influenced by the extent of amyloid plaque deposition, which may serve as a binding reservoir in the CNS.

Metabolism:
As a humanized IgG1 monoclonal antibody, donanemab is metabolized primarily via proteolytic catabolism into small peptides and amino acids by the reticuloendothelial system and target-mediated internalization. It is not metabolized by hepatic cytochrome P450 enzymes, minimizing potential for CYP-mediated drug interactions. The clearance rate is affected by target antigen binding and subsequent internalization, a process known as target-mediated drug disposition.

Elimination:
Donanemab elimination follows typical monoclonal antibody kinetics with clearance mediated through proteolytic degradation in the reticuloendothelial system. Its half-life is estimated to allow once-monthly dosing, supporting convenient administration schedules. Elimination pathways are dose and disease-state dependent; amyloid burden reduction may alter clearance over time. There is no significant renal or hepatic excretion of intact drug molecules, aligning with antibody pharmacokinetics.

Dosage Forms

Available Dosage Forms:
- Injection for intravenous use in a single-dose vial
- Strength: 350 mg per 20 mL (concentration of 17.5 mg/mL)

Dosages for Adults and Adolescents:
- Kisunla is administered as an intravenous infusion every 4 weeks.
- Initial dosing schedule includes dose escalation over the first four infusions:
- Infusion 1: 350 mg
- Infusion 2: 700 mg
- Infusion 3: 1,050 mg
- From Infusion 4 onward: 1,400 mg every 4 weeks
- Each infusion is administered over approximately 30 minutes.
- Dose titration reduces the risk of infusion-related adverse events.
- Dose modifications are recommended if amyloid-related imaging abnormalities (ARIA) occur.

Specific Patient Populations:
- Patients at higher risk for ARIA (e.g., APOE ε4 homozygous individuals) may require close monitoring and dose adjustments.
- The safety and efficacy in pediatric populations have not been established; usage restricted to adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
- Dosage adjustment guidance for renal or hepatic impairment is not required due to antibody metabolism.

Clinical Guidelines:
- Dosing should be paused or discontinued upon amyloid plaque reduction to minimal levels as determined by amyloid PET imaging.
- If a scheduled infusion is missed, administration should resume at the same dose as soon as possible, maintaining the 4-week interval.
- Pre-infusion dilution is mandatory prior to administration.
- Concomitant use and timing with other Alzheimer's medications can be individualized based on clinical judgement.

Mechanism Of Action

Donanemab, the active ingredient in Kisunla, is a humanized IgG1 monoclonal antibody designed to selectively target and bind to a specific epitope of amyloid-beta plaques present in the brain of patients with Alzheimer's disease. These plaques consist primarily of aggregated amyloid beta peptide deposits that are implicated in the pathogenesis and clinical progression of Alzheimer's disease. By binding directly to the amyloid beta plaques, donanemab facilitates their clearance from the brain.

The antibody activates microglia-mediated phagocytosis through Fc receptor engagement upon binding to amyloid plaques, enhancing the immune system's ability to clear these pathological aggregates. This mechanism reduces plaque burden, resulting in slowing of neurodegenerative processes. Donanemab’s specificity for the modified pyroglutamate amyloid-beta epitope (pE3-Aβ) distinguishes it from other anti-amyloid agents, allowing targeted action with minimized off-target effects.

Biochemically, the removal of amyloid plaques is hypothesized to disrupt the cascade leading to neurofibrillary tangle formation and neuronal death. By reducing amyloid burden, donanemab ultimately slows clinical decline in cognitive and functional domains, as evidenced by reductions in integrated Alzheimer's Disease Rating Scale (iADRS) and Clinical Dementia Rating – Sum of Boxes (CDR-SB) scores in clinical trials.

Comparatively, unlike cholinesterase inhibitors or NMDA receptor antagonists, which manage symptoms, donanemab modifies disease pathology. Clinical studies, including the TRAILBLAZER-ALZ 2 trial, have demonstrated that donanemab slows disease progression by approximately 20-35% depending on the disease stage and biomarkers, establishing its role as a disease-modifying therapy. Ongoing research continues to elucidate long-term outcomes and potential synergistic effects when combined with other therapeutic agents.

Pharmacological Actions

Selective binding to pyroglutamate-modified amyloid-beta plaques in the brain’s extracellular space.
Activation of microglia via Fc receptor-mediated phagocytosis to enhance amyloid plaque clearance.
Reduction of cerebral amyloid plaque burden to slow Alzheimer’s disease progression.
Modulation of neuroinflammatory pathways secondary to amyloid clearance.
Disease-modifying action through interference with amyloid cascade hypothesis.
Potential improvement in cognitive and functional measures by slowing neuronal loss.
Intravenous administration results in systemic exposure sufficient to cross the blood-brain barrier at therapeutic concentrations.
Minimal off-target binding due to high specificity for amyloid beta species containing pyroglutamate modification.
Pharmacodynamic effects correlate with biomarker changes shown in amyloid PET imaging.
Dose-dependent pharmacologic responses with initial slow titration to improve tolerability.
Therapeutic antibody with low potential for cytochrome P450-mediated drug interactions.
Long half-life supporting once-monthly dosing regimen for maintenance therapy.
Immunogenicity is low but potential for anti-drug antibody formation exists.
Contributes to delayed clinical decline in memory, thinking, and daily functioning in Alzheimer’s disease.

Therapeutic Or Clinical Uses

Treatment of mild cognitive impairment (MCI) due to Alzheimer's disease.
Management of mild dementia stage Alzheimer’s disease to slow progression.
Used to reduce amyloid beta plaques in the brain, attenuating pathological processes.
Indicated as a disease-modifying therapy to delay clinical decline in cognition and function.
Provided as a monthly intravenous infusion for ease of dosing adherence.
Adjunctive therapy option alongside symptomatic Alzheimer's disease treatments.
Supports prolonged maintenance of daily activities and cognitive abilities.
Clinically tested and approved for patients confirmed by amyloid PET imaging.
Considered for patients with early symptomatic Alzheimer’s disease with low to medium tau pathology.
Facilitates enrollment in registries tracking Alzheimer’s treatment outcomes.
Useful in patients without contraindications such as severe allergic reactions or active brain hemorrhage.
Applied as part of comprehensive Alzheimer’s management including cognitive and functional assessments.
May be used concomitantly with other Alzheimer’s medications following clinical evaluation.
Supports improved quality of life through deceleration of neurodegeneration.
Potential to be integrated into individualized Alzheimer’s treatment plans based on biomarker testing.

Side Or Adverse Effects

Headache occurring in at least 10% of treated patients.
Brain swelling (ARIA-E) detected on MRI, sometimes asymptomatic but may cause neurological symptoms.
Microhemorrhages or small spots of bleeding in or on the surface of the brain (ARIA-H).
Serious allergic reactions including facial, lip, mouth, or eyelid swelling.
Infusion-related reactions such as chills, sweating, skin irritation, headache, nausea, vomiting, chest pain, and breathing difficulties.
Dizziness and confusion potentially associated with ARIA symptoms.
Nausea reported during or after infusion.
Risk of more extensive brain hemorrhage in patients on antithrombotic therapy.
Rare seizures related to cerebral edema or ARIA complications.
Potential development of anti-drug antibodies with unclear clinical significance.
Fatigue and flu-like symptoms post-infusion.
Localized infusion site reactions such as redness or discomfort may occur.
Potential transient vision changes linked with ARIA-related cerebral changes.
Uncommon occurrences of serious neurologic events requiring medical intervention.
Possible worsening of pre-existing neurological symptoms in susceptible individuals.

Precautions

Perform baseline and periodic MRI scans to monitor for ARIA before and during therapy.
Screen for genetic risk factors (e.g., APOE ε4 homozygosity) which elevate ARIA risk.
Monitor patients closely during infusions and educate regarding signs of infusion reactions.
Adjust dosing or pause therapy if ARIA-E or ARIA-H is detected on imaging to reduce complications.
Use caution in patients concomitantly taking anticoagulants or antithrombotic medications due to increased bleeding risk.
Ensure readiness to manage severe allergic reactions during infusion administration.
Advise patients to carry information about Kisunla treatment and ARIA risk, including symptoms that mimic stroke.
Not recommended for patients with history of serious hypersensitivity to donanemab components.
Assess pregnancy status as safety in pregnancy and lactation is unknown; weigh risks versus benefits.
Encourage participation in registries to collect safety and efficacy data post-approval.
Missed infusions should be administered promptly to maintain therapeutic efficacy.
Avoid shaking the drug vial and adhere strictly to storage guidelines for drug integrity.
Diluted drug must be used immediately or stored appropriately up to specified limits to prevent degradation.
Evaluate risks and benefits continuously due to the progressive nature of Alzheimer’s disease and treatment side effects.
Educate caregivers and patients to promptly report neurological changes or infusion-related symptoms.

Warnings

Amyloid Related Imaging Abnormalities (ARIA), including brain edema (ARIA-E) and microhemorrhages (ARIA-H), are common and can be serious or fatal.
ARIA can be asymptomatic but may cause headache, dizziness, confusion, seizures, vision changes, nausea, and gait disturbance.
Patients with ARIA symptoms require immediate medical evaluation and may need treatment interruption.
Higher ARIA risk in patients who are homozygous carriers of the APOE ε4 allele.
Concurrent use of antithrombotic agents increases risk of brain bleeding complications.
MRI monitoring before and during treatment is mandatory to detect ARIA early and minimize risks.
Serious hypersensitivity reactions including anaphylaxis can occur during or after infusion.
Infusion reactions may require slowing or stopping the infusion and administration of supportive medications.
Dose adjustments or discontinuation may be necessary based on the extent of ARIA or adverse reactions.
Treatment should be administered by healthcare professionals in facilities equipped to manage potential severe reactions.
Patients should carry identification indicating their use of Kisunla due to ARIA symptom overlap with cerebrovascular events.
Limited safety data in pregnancy and breastfeeding; use only if benefits outweigh risks.
Not advised for patients with known severe allergic reactions to donanemab or its excipients.
Continuous benefit-risk assessment is essential given the progressive nature of Alzheimer's and potential adverse events.
Clinical trial data have demonstrated slowing of disease progression, but individual response may vary.

Contraindication

Known hypersensitivity or serious allergic reactions to donanemab-azbt or any of its inactive ingredients.
Patients with active or recent brain hemorrhage or bleeding disorders.
Concomitant use with other investigational amyloid-targeting monoclonal antibodies is not recommended.
Severe infusion reaction history related to monoclonal antibodies without appropriate medical support.
Patients unable to comply with MRI monitoring to detect ARIA during treatment.
Absolute contraindication in patients with prior anaphylaxis to any component of the drug formulation.
Use contraindicated if severe uncontrolled systemic infections are present.
Contraindicated in patient populations lacking clinical trial data, such as pediatrics and pregnant women, without compelling justification.
Not recommended where risk outweighs benefit in advanced Alzheimer’s disease with extensive neurodegeneration.
Patients with uncontrolled bleeding risk or on high-dose anticoagulation may be contraindicated.
Inability to safely receive intravenous infusions or to tolerate volume administration.
Severe renal or hepatic impairment is not a contraindication per se but requires clinical judgment.
Do not administer if drug vial integrity is compromised or storage recommendations were violated.
Known sensitivity to polysorbate 80 or other excipients in the formulation.
History of severe infusion-related reactions to similar biologics without prophylactic premedication.

Drug Interactions

Concomitant use with antithrombotic agents (e.g., warfarin, direct oral anticoagulants) increases risk of intracerebral bleeding.
No significant cytochrome P450-mediated drug interactions expected due to monoclonal antibody metabolism.
Potential pharmacodynamic interaction with other anti-amyloid monoclonal antibodies; concurrent use not recommended.
Pre-infusion administration of acetaminophen, antihistamines, or corticosteroids can mitigate infusion-related reactions.
No known interactions with common Alzheimer's symptom management drugs (e.g., donepezil, memantine) observed in clinical trials.
No reported interactions with herbal supplements or vitamins, but caution advised due to limited data.
Immunosuppressive therapies may alter the pharmacodynamics and efficacy of donanemab.
Vaccines: The influence of immune-modulating therapies on vaccine efficacy may require clinical monitoring.
Potential interference with amyloid PET imaging accuracy if administered recently prior to imaging.
Patient’s polypharmacy status should be evaluated to monitor for overlapping adverse effects.
May affect coagulation parameters indirectly due to risk of hemorrhagic events when combined with blood thinners.
Pre-medication to prevent infusion reactions has potential interaction with sedatives or antipyretics.
Herbals with anticoagulant effects (e.g., ginkgo biloba) may further increase bleeding risk when combined.
No significant drug interactions with cytochrome P450 substrates, inducers, or inhibitors.
No known impact on renal or hepatic enzyme pathways; dose adjustments for renal/hepatic impairment not required.

Preparations Of The Drug

Kisunla is supplied as an injectable solution in a single-dose vial containing 350 mg donanemab in 20 mL (17.5 mg/mL).
The solution requires dilution prior to intravenous infusion administration.
The vial is for single use only; any unused portion must be discarded.
Unopened vials must be stored refrigerated between 2°C to 8°C (36°F to 46°F) and protected from light.
Vials should not be frozen or shaken to maintain protein integrity.
If refrigeration is unavailable, vials may be stored at room temperature (20°C to 25°C) for up to 3 days before use.
The diluted infusion solution is stable for up to 72 hours refrigerated or 12 hours at room temperature, including infusion time.
Diluted solutions must not be frozen.
Administration performed by trained healthcare professionals using standardized infusion protocols.
Premedication with antihistamines, acetaminophen, or steroids may be administered as prophylaxis against infusion reactions.
Each vial contains inactive ingredients: anhydrous citric acid, polysorbate 80, sodium citrate, sucrose, and Water for Injection, USP.
Packaging includes detailed prescribing information for dosage preparation, administration, and storage conditions.
Available through prescription with appropriate prior authorization and monitoring requirements per regulatory guidance.
Manufactured and distributed by Eli Lilly and Company, Indianapolis, IN, USA.
Biosimilar products are not currently approved; Kisunla is the reference biologic for donanemab-azbt.